Michael Hecht Olsen

Michael Hecht Olsen

Auto-generated profile, based on publicly available information

Michael Hecht Olsen

Department of Clinical Medicine, University of Copenhagen , Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
LHLaura Hesseldal
Laura Hesseldal
JCJeanette Reffstrup Christensen
Jeanette Reffstrup Christensen
TOThomas Bastholm Olesen
Thomas Bastholm Olesen
MOMichael Hecht Olsen
Michael Hecht Olsen
PPernille Ravn Jakobsen
Pernille Ravn Jakobsen
CBCarl Joakim Brandt
Carl Joakim Brandt
Background: Long-term weight loss in people living with obesity can reduce the risk and progression of noncommunicable diseases. Observational studies suggest that digital coaching can lead to long-term weight loss. Objective: We investigated whether an eHealth lifestyle coaching program for people living with obesity with or without type 2 diabetes led to significant, long-term (12-month) weight loss compared to usual care. Methods: In a randomized controlled trial that took place in 50 municipalities in Denmark, 340 people living with obesity with or without type 2 diabetes were enrolled from April 16, 2018, to April 1, 2019, and randomized via an automated computer algorithm to an intervention (n=200) or a control (n=140) group. Patients were recruited via their general practitioners, the Danish diabetes organization, and social media. The digital coaching intervention consisted of an initial 1-hour face-to-face motivational interview followed by digital coaching using behavioral change techniques enabled by individual live monitoring. The primary outcome was change in body weight from baseline to 12 months. Results: Data were assessed for 200 participants, including 127 from the intervention group and 73 from the control group, who completed 12 months of follow-up. After 12 months, mean body weight and BMI were significantly reduced in both groups but significantly more so in the intervention group than the control group (–4.5 kg, 95% CI –5.6 to –3.4 vs –1.5 kg, 95% CI –2.7 to –0.2, respectively; P<.001; and –1.5 kg/m2, 95% CI –1.9 to –1.2 vs –0.5 kg/m2, 95% CI –0.9 to –0.1, respectively; P<.001). Hemoglobin A1c was significantly reduced in both the intervention (–6.0 mmol/mol, 95% CI –7.7 to –4.3) and control (–4.9 mmol/mol, 95% CI –7.4 to –2.4) groups, without a significant group difference (all P>.46). Conclusions: Compared to usual care, digital lifestyle coaching can induce significant weight loss for people living with obesity, both with and without type 2 diabetes, after 12 months. Trial Registration: ClinicalTrials.gov NCT03788915; https://clinicaltrials.gov/ct2/show/NCT03788915

23 May 2022 in JMIR Preprints
Verified
Preprint
Open access
LHLaura Hesseldal
Laura Hesseldal
JCJeanette Reffstrup Christensen
Jeanette Reffstrup Christensen
TOThomas Bastholm Olesen
Thomas Bastholm Olesen
MOMichael Hecht Olsen
Michael Hecht Olsen
PPernille Ravn Jakobsen
Pernille Ravn Jakobsen
CBCarl Joakim Brandt
Carl Joakim Brandt
BACKGROUND Long-term weight loss among subjects with obesity can reduce the risk and progression of noncommunicable diseases (NCDs). Observational studies suggest that digital coaching can lead to long-term weight loss. OBJECTIVE We investigated whether an eHealth lifestyle coaching program (LIVA) for subjects with obesity with or without type 2 diabetes (T2D) leads to significant long-term (more than 6 months) weight loss compared to usual care. METHODS In a randomized controlled trial that took place in 50 municipalities in Denmark, 340 subjects with obesity with or without T2D were enrolled from April 16, 2018, to April 1, 2019, and randomized via an automated computer algorithm to an intervention (200) or a control (140) group. Patients were recruited via their general practitioners, the Danish diabetes organization, and social media. The digital coaching intervention comprised of an initial one-hour face-to-face motivational interview followed by digital coaching using behavioral change techniques enabled by individual live monitoring. Primary outcome was change in body weight from baseline to 6 and 12 months. RESULTS Data were assessed for 235 participants, 149 from the intervention group and 86 from the control group who completed 6 and/or 12 months follow-up. After 12 months mean body weight and body mass index were reduced significantly in both groups but significantly more in the intervention group (–4.6 (-5.7; -3.4) kg vs. -1.4 (-2.6; -0.1) kg, P<.001 and -1.5 (-1.9; -1.2) kg/m2 vs. -0.5 (-0.9; -0.1) kg/m2, P<.001). Hemoglobin A1c (HbA1c) was significantly reduced in both the intervention (-6.0 (-7.7; -4.3) mmol/mol) and the control group (-4.9 (-7.4; -2.4) mmol/mol) without significant group difference. CONCLUSIONS Compared to usual care, digital lifestyle coaching can induce significant weight loss in obese subjects both with and without T2D after 12 months. CLINICALTRIAL ClinicalTrials.gov NCT03788915; https://clinicaltrials.gov/ct2/show/NCT03788915

25 March 2026 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JNJohanne E Nyen
Johanne E Nyen
AKAnna Meta D Kristensen
Anna Meta D Kristensen
TDToril Dammen
Toril Dammen
AZAnn-Dorthe Zwisler
Ann-Dorthe Zwisler
MOMichael Hecht Olsen
Michael Hecht Olsen
JMJohn Munkhaugen
John Munkhaugen
Symptoms of depression and anxiety are common among patients with myocardial infarction (MI) and associated with reduced health-related quality of life and increased risk of recurrent major adverse cardiovascular events.1,2 The underlying causes of post-MI depression and anxiety are still a matter of elucidation.3 They may be pre-existing conditions caused by environmental, biological or genetic factors, as well as a response to the MI event itself and/or side effects of the treatments initiated.3

25 May 2026 in European Heart Journal
Verified
Journal Article
Closed access
AKAnna Meta Dyrvig Kristensen
Anna Meta Dyrvig Kristensen
JJJarle Jortveit
Jarle Jortveit
THTherese Holmager
Therese Holmager
DADan Atar
Dan Atar
MOMichael Hecht Olsen
Michael Hecht Olsen
SHSigrun Halvorsen
Sigrun Halvorsen
Background and Aims: In patients with myocardial infarction (MI), no heart failure, and left ventricular ejection fraction (LVEF) ≥ 40%, the combined BETAMI-DANBLOCK trial showed that beta-blockers reduced the risk of all-cause mortality or major adverse cardiovascular events. This study evaluated the representativeness of the trial. Methods: Participants in BETAMI (n = 2867) and DANBLOCK (n = 2707) were compared with a cohort of revascularized MI patients with LVEF ≥40%, and no heart failure from the Norwegian Myocardial Infarction Registry (the NORMI cohort)(n = 20 804). Baseline characteristics were evaluated, and absolute risks of all-cause mortality and/or MI were estimated. A transportability analysis was conducted by weighting the BETAMI-DANBLOCK population according to the NORMI cohort. Results: Median age was 66 years (interquartile range [IQR]: 57–74) in the NORMI cohort and 63 years (IQR: 55–70) in BETAMI and DANBLOCK. Patients in the NORMI cohort had a higher prevalence of diabetes, previous coronary artery disease, and LVEF 40–49%, compared with trial participants. At 3-year follow-up, the absolute risk of all-cause mortality or MI was 12.0% in the NORMI cohort, 7.7% in BETAMI, and 7.8% in DANBLOCK. Corresponding risks of MI were 6.3%, 5.6%, and 4.3%, respectively. The treatment effects of beta-blockers were similar when the trial population was weighted according to the characteristics of the NORMI cohort. Conclusions: Compared with the NORMI cohort, participants in BETAMI and DANBLOCK were younger, had a lower proportion of certain comorbidities, and experienced a lower risk of all-cause mortality and MI. Despite these differences, the effect of beta-blockers remained consistent when the trial population was weighted according to the NORMI cohort.

4 April 2026 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
THTherese Lucia Friis Holmager
Therese Lucia Friis Holmager
AKAnna Meta Dyrvig Kristensen
Anna Meta Dyrvig Kristensen
MFMorten Wang Fagerland
Morten Wang Fagerland
DADan Atar
Dan Atar
MOMichael Hecht Olsen
Michael Hecht Olsen
EPEva Prescott
Eva Prescott
Aims: Registry-based randomized clinical trials are increasingly applied in clinical research, providing advantages in feasibility and data capture. However, registry-based data may introduce bias through misclassification or missing information. Methods and results: In the BETAMI-DANBLOCK trial, 5574 patients with myocardial infarction (MI) and no heart failure were randomized to beta-blocker or no beta-blocker therapy. The primary endpoint events (all-cause mortality, MI, ischemic stroke, heart failure, unplanned coronary revascularization, and malignant ventricular arrhythmias) were identified from the Danish/Norwegian national patient registries, self-reported questionnaires, and medical records. All registry-identified events, except all-cause mortality, underwent blinded adjudication. We compared non-adjudicated and adjudicated events by calculating incidence rates and hazard ratios (HRs) for beta-blocker therapy vs. controls. National registries captured 99.7% of primary endpoint events registered by self-report and medical records. Of the primary endpoint events identified through the registries, 75% were confirmed by adjudication (incidence rate 6.23 vs. 4.43/100 person-years). The confirmation rate was lower during the first 6 months and varied by event type (from 92% for ischaemic stroke to 45% for unplanned coronary revascularizations and heart failure). Estimated treatment effects were consistent for the primary endpoint with non-adjudicated and adjudicated events (HR 0.88, 95% confidence interval (CI): 0.78–0.98 and HR 0.85, 95% CI: 0.75–0.98, respectively), with no apparent differences across event types except for heart failure and revascularization. Conclusion: Registry data provided effect estimates of beta-blockers comparable to adjudicated data. However, adjudication substantially reduced the number of cardiovascular endpoint events and event-specific misclassification appeared, particularly during the first months after the index event. Trial registration number: BETAMI-DANBLOCK ClinicalTrials.gov numbers, NCT03646357 and NCT03778554